Table A1.
Specific clinical characteristics of overall population and according to Heart Failure Stages A and B (SAHF, SBHF).
| Overall (n = 885) | SAHF (n = 644) |
SBHF (n = 241) |
p-Value | |
|---|---|---|---|---|
| Arterial Hypertension (n,%) | 569 (64%) | 377 (59%) | 192 (80%) | <0.0001 |
| Diabetes (n,%) | 125 (14%) | 69 (11%) | 56 (23%) | <0.0001 |
| Dyslipidemia (n,%) | 377 (43%) | 251 (39%) | 126 (43%) | <0.0001 |
| Smoke (n,%) | 112 (13%) | 85 (13%) | 27 (11%) | 0.4 |
| CAD (n,%) | 66 (7%) | 25 (4%) | 41 (17%) | <0.0001 |
| CKD (n,%) | 25 (3%) | 11 (2%) | 14 (6%) | 0.002 |
| Dyalisis (n,%) | 6 (0.7%) | 1 (0.1%) | 5 (2%) | 0.004 |
| Tyroid disease (n,%) | 88 (10%) | 60 (9%) | 28 (12%) | 0.4 |
| PAD (n,%) | 72 (8%) | 40 (6%) | 32 (13%) | 0.001 |
| Other (n,%) | 157 (18%) | 107 (17%) | 50 (21%) | 0.2 |
| ACEi (n,%) | 247 (28%) | 155 (24%) | 92 (38%) | <0.0001 |
| ARB (n,%) | 205 (23%) | 126 (20%) | 79 (33%) | <0.0001 |
| Beta blockers (n,%) | 197 (22%) | 121 (19%) | 76 (32%) | <0.0001 |
| Calcium channel blockers (n,%) | 151 (17%) | 92 (14%) | 59 (25%) | 0.0006 |
| Diuretics (n,%) | 243 (27%) | 143 (22%) | 100 (42%) | <0.0001 |
| Alpha blockers (n,%) | 39 (5%) | 24 (4%) | 15 (6%) | 0.1 |
| Acetylsalicylic acid (n,%) | 192 (22%) | 106 (17%) | 86 (36%) | <0.0001 |
| Statins (n,%) | 205 (23%) | 114 (18%) | 91 (38%) | <0.0001 |
| Digoxin (n,%) | 4 (0.4%) | 1 (0.2%) | 3 (1%) | 0.05 |
| Antiarrythmics (n,%) | 27 (3%) | 15 (2%) | 12 (5%) | 0.05 |
| NTG (n,%) | 23 (3%) | 3 (0.5%) | 20 (8%) | <0.0001 |
Abbreviations: CAD, Coronary Artery Disease; CKD, Chronic Kidney Disease; PAD, Peripheral Artery Disease; ACEi, Angiotensin Converting Enzyme Inhibitor; ARB, Angiotensin Receptor Blocker; NTG, Nitroglycerin.